Human CXCL1/GRO alpha Quantikine ELISA Kit
Human CXCL1/GRO alpha Quantikine ELISA Kit
深圳9游总区生物优势代理美国R&DELISA系列产品试剂盒，价格优势，货期短，欢迎来电咨询0755-33164177！
Human CXCL1/GRO alpha Quantikine ELISA Kit Summary
货号：DGR00B 规格：96T
Assay Length
4.25-4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (200 uL), Serum (200 uL), Platelet-poor EDTA Plasma (200 uL), Platelet-poor Heparin Plasma (200 uL), Platelet-poor Citrate Plasma (200 uL)
Assay Range
31.3 - 1,000 pg/mL (Cell Culture Supernates, Serum, Platelet-poor EDTA Plasma, Platelet-poor Heparin Plasma, Platelet-poor Citrate Plasma)
Specificity
Natural and recombinant human GRO alpha.
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.
Product Summary
The Quantikine® Human CXCL1/GRO alpha Immunoassay is a 4.25-4.5 hour solid phase ELISA designed to measure human GRO alpha in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human GRO alpha and antibodies raised against the recombinant protein. This immunoassay has been shown to accurately quantitate the recombinant factor. Results obtained using natural human GRO alpha showed linear curves that were parallel to the
standard curves obtained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for natural human GRO alpha.
Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components
Cell Culture Supernates
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
20
|
20
|
20
|
20
|
20
|
20
|
|
Mean
|
41.8
|
140
|
373
|
48.7
|
157
|
379
|
|
Standard Deviation
|
0.91
|
5.98
|
15.7
|
2.9
|
12.3
|
29.8
|
|
CV%
|
2.2
|
4.3
|
4.2
|
6
|
7.8
|
7.8
|
Serum, Platelet-poor EDTA Plasma, Platelet-poor Heparin Plasma, Platelet-poor Citrate Plasma
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
20
|
20
|
20
|
20
|
20
|
20
|
|
Mean
|
61.4
|
251
|
736
|
62.8
|
252
|
734
|
|
Standard Deviation
|
2.2
|
6
|
20
|
3.6
|
11.9
|
38.9
|
|
CV%
|
3.6
|
2.4
|
2.7
|
5.7
|
4.7
|
5.3
|
Recovery
The recovery of human GRO alpha spiked to levels throughout the range of the assay in various matrices was evaluated.
|
Sample Type
|
Average % Recovery
|
Range %
|
|
Cell Culture Media (n=4)
|
99
|
92-105
|
|
Platelet-poor Citrate Plasma (n=4)
|
90
|
80-98
|
|
Platelet-poor EDTA Plasma (n=4)
|
93
|
86-102
|
|
Platelet-poor Heparin Plasma (n=4)
|
95
|
83-109
|
|
Serum (n=4)
|
98
|
87-108
|
